IDH1 and neoplasm: As shown in Table 4, EGFR CNG (HR =2.31, 95% CI =1.44-3.69, P =0.001), IDH1 mutations (HR =0.3, 95% CI =0.17-0.53, P <0.001), increasing age (HR =1.52, 95% CI =1.16-1.98, P =0.002), advanced tumor stage (HR =1.92, 95% CI =1.47-2.48, P <0.001) and tumor recurrence (HR =44.86, 95% CI =6.16-327.00, P <0.001) were significantly correlated with poor survival, while the patients receiving radiotherapy (HR =0.47, 95% CI=0.30-0.75, P <0.001) and the patients with epilepsy (HR =0.41, 95% CI=0.25-0.66, P <0.001) were more likely to have a better prognosis.